Stivarga regorafenib: Additional Phase III data

Additional data from the double-blind, international Phase III RESORCE trial in about 573 patients with unresectable HCC whose disease progressed after treatment with Nexavar sorafenib

Read the full 259 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE